Direct Oral Anticoagulants and Cancer-Associated Thrombosis Management. Where Do We Stand in 2019?

Direct Oral Anticoagulants and Cancer-Associated Thrombosis Management. Where Do We Stand in 2019?

Direct oral anticoagulants (DOACs) are now widely used for the management of venous thromboembolism (VTE) that now includes cancer-associated thrombosis. This review summarizes recent data on VTE prophylaxis and treatment, new challenges, guidelines, and updates as well as the current place for DOAC...

Full description

Bibliographic Details
Main Authors: Eduardo Ramacciotti MD, PhD, Leandro B. Agati PhD, Roberto Augusto Caffaro MD, PhD, Giuliano G. Volpiani MD, Renato D. Lopes MD, PhD, Anthony J. Comerota MD, Jawed Fareed PhD
Format: Article
Language:English
Published: SAGE Publishing 2019-06-01
Series:Clinical and Applied Thrombosis/Hemostasis
Online Access:https://doi.org/10.1177/1076029619856433

Internet

https://doi.org/10.1177/1076029619856433

Similar Items